Related Papers
Onkologie
Patients with aggressive B-cell lymphomas display distinct chemokine receptor profile and an association of low CCR7 expression and favorable cancer specific survival
2014 •
Helmut Schaider
Onkologie
Distinct chemokine receptor profiles in Richter's transformation compared to de-novo diffuse large B-cell lymphoma and germinal center B-cells
2014 •
Helmut Schaider
Journal of Reproductive Immunology
Concordance between peripheral and decidual NK cell subsets and killer immunoglobulin-like receptors in women with recurrent spontaneous miscarriages
Noha Afifi
The Mathematics Enthusiast
Polysemy of symbols: Signs of ambiguity
2010 •
Ami Mamolo
Geburtshilfe und Frauenheilkunde
Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) – Recommendations and Statements for Girls and Women
Maren Goeckenjan
Aim The aim of this official guideline published by the German Society of Gynecology and Obstetrics (DGGG) and coordinated with the German Society of Urology (DGU) and the German Society of Reproductive Medicine (DGRM) is to provide consensus-based recommendations, obtained by evaluating the relevant literature, on counseling and fertility preservation for prepubertal girls and boys as well as patients of reproductive age. Statements and recommendations for girls and women are presented below. Statements or recommendations for boys and men are not the focus of this guideline. Methods This S2k guideline was developed at the suggestion of the guideline commission of the DGGG, DGU and DGRM and represents the structured consensus of representative members from various professional associations (n = 40). Recommendations The guideline provides recommendations on counseling and fertility preservation for women and girls which take account of the patientʼs personal circ*mstances, the planne...
Haematologica
Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients
Francoise Mechinaud
Among 100 patients with acute lymphoblastic leukemia (ALL), 15 B-ALL patients were found positive for surface Her2/neu expression. The incidence in children was only 3.4% compared to 31% in adults (p=0.001). Considering only adult B-ALL patients (n=38), surface Her2/neu expression was associated with chemoresistance (50% versus 11%, p=0.03) suggesting that it could be a prognostic marker of poor clinical outcome in ALL.
Leukemia & lymphoma
Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation
2015 •
Cornelia Brendel
Gain-of-function mutations in the RAS and FLT3 genes are frequently found in cells of acute myeloid leukemia (AML), leading to constitutive activation of signaling pathways that regulate fundamental cellular processes, and are therefore attractive targets for AML therapy. The multi-targeted kinase inhibitor sorafenib is efficacious in AML with FLT3-internal tandem duplication (ITD), but resistance to therapy is an important clinical problem. It is unclear whether AML lacking FLT3-ITD responds to sorafenib. Using AML cell lines, we have shown that a low concentration of sorafenib induces opposing effects depending on the oncogenic background. In FLT3-ITD positive cells sorafenib blocks Erk activity and cell proliferation, and triggers apoptosis. However, in cells lacking FLT3-ITD, sorafenib paradoxically activates Erk2, and stimulates cellular proliferation and metabolic activity. Thus, depending on the genetic context, sorafenib is a beneficial inhibitor or paradoxical activator of ...
Leukemia
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
2021 •
Hartmut Link
Early results of the randomized placebo-controlled SORAML trial showed that, in patients with newly diagnosed acute myeloid leukaemia (AML), sorafenib led to a significant improvement in event-free (EFS) and relapse-free survival (RFS). In order to describe second-line treatments and their implications on overall survival (OS), we performed a study after a median follow-up time of 78 months. Newly diagnosed fit AML patients aged ≤60 years received sorafenib (n = 134) or placebo (n = 133) in addition to standard chemotherapy and as maintenance treatment. The 5-year EFS was 41 versus 27% (HR 0.68; p = 0.011) and 5-year RFS was 53 versus 36% (HR 0.64; p = 0.035). Allogeneic stem cell transplantation (allo SCT) was performed in 88% of the relapsed patients. Four years after salvage allo SCT, the cumulative incidence of relapse was 54 versus 35%, and OS was 32 versus 50%. The 5-year OS from randomization in all study patients was 61 versus 53% (HR 0.82; p = 0.282). In conclusion, the add...
Journal of Environmental Chemical Engineering
Antibacterial electrospun chitosan-PEO/TEMPO-oxidized cellulose composite for water filtration
2021 •
Ingrid Berenice Sanchez Carrillo
HemaSphere
Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020
2020 •
Lisbeth Kirstine Rosenbek Minet
